SGLT2 Inhibitor Initiation, Dosing, and Contraindications
Initiate an SGLT2 inhibitor in all adults with type 2 diabetes and eGFR ≥20 mL/min/1.73 m² using canagliflozin 100 mg, dapagliflozin 10 mg, or empagliflozin 10 mg once daily—these are first-line therapies independent of HbA1c level or current glycemic control. 1, 2, 3
When to Initiate SGLT2 Inhibitors
High-Priority Indications (Start Immediately)
Type 2 diabetes with chronic kidney disease:
- eGFR ≥20 mL/min/1.73 m² with albuminuria ≥200 mg/g (≥20 mg/mmol) – Strong recommendation for all patients in this category 1, 2, 4
- eGFR ≥20 mL/min/1.73 m² with heart failure – Regardless of albuminuria level 4, 5
- eGFR 20-45 mL/min/1.73 m² with albuminuria <200 mg/g – Suggested for kidney protection even with lower albuminuria 4
Heart failure with reduced ejection fraction (HFrEF):
- Initiate dapagliflozin or empagliflozin in all HFrEF patients regardless of diabetes status 6, 7
- Benefits occur on top of maximally tolerated guideline-directed medical therapy, but early initiation is reasonable given residual risk 6
Established atherosclerotic cardiovascular disease:
- All three agents (empagliflozin, canagliflozin, dapagliflozin) reduce major adverse cardiovascular events 7, 8, 3
- Empagliflozin and canagliflozin carry specific FDA indications for cardiovascular risk reduction 7, 8
Moderate-Priority Indications
- Type 2 diabetes patients >50 years with additional cardiovascular risk factors to prevent heart failure hospitalization 6
- Albuminuric renal disease with or without type 2 diabetes 6
Recommended Dosing by Agent and Renal Function
Starting Doses (No Titration Required for CV/Renal Protection)
| Agent | Standard Dose | eGFR 45-59 | eGFR 30-44 | eGFR 20-29 |
|---|---|---|---|---|
| Empagliflozin | 10 mg daily | 10 mg daily | 10 mg daily | 10 mg daily [2,7,3] |
| Dapagliflozin | 10 mg daily | 10 mg daily | 10 mg daily | 10 mg daily [2,7,3] |
| Canagliflozin | 100 mg daily | Max 100 mg daily | Max 100 mg daily | Not recommended for initiation [2,7,3] |
Key dosing principles:
- No dose titration is required to achieve cardiovascular or renal protection because a graded dose-response relationship has not been demonstrated 3
- If additional glucose-lowering is needed, empagliflozin may be increased to 25 mg and canagliflozin to 300 mg (only when eGFR ≥60 mL/min/1.73 m²) 7, 8, 3
- Dapagliflozin remains at 10 mg regardless of glycemic need 3
Agent Selection by Clinical Context
For diabetic kidney disease with significant albuminuria:
- Prioritize canagliflozin 100 mg daily—it has the strongest evidence and FDA approval for reducing kidney failure, doubling of serum creatinine, cardiovascular death, and heart failure hospitalization in patients with diabetic nephropathy and albuminuria 1, 7, 3
For heart failure:
- Prioritize dapagliflozin 10 mg daily—it holds the broadest FDA indication for HFrEF and demonstrated benefits regardless of diabetes status 6, 7, 3
- Empagliflozin 10 mg daily is an alternative with proven heart failure benefits 6, 3
For established cardiovascular disease:
- All three agents are appropriate; empagliflozin and canagliflozin carry specific FDA indications for cardiovascular risk reduction 7, 8, 3
Contraindications and Cautions
Absolute Contraindications
- Type 1 diabetes 6
- History of serious hypersensitivity reaction to the specific agent 7
- Patients on dialysis or with end-stage renal disease (though dapagliflozin may be continued if already established) 4, 7
Relative Contraindications and High-Risk Situations
Active genital infections:
- Women have 10-15% risk of genital mycotic infections, uncircumcised men and those with previous infections are at highest risk 6, 5
- Typically managed with antifungal drugs without discontinuation 6
Risk of diabetic ketoacidosis:
- Incidence 0.1%, but can present with normal or modestly elevated glucose (<14 mmol/L) 6
- Withhold during prolonged fasting, surgery (discontinue 2-4 days before), or critical medical illness 1, 2, 1, 7
Volume depletion risk:
- Consider reducing thiazide or loop diuretic doses before initiation in patients with tenuous volume status, concurrent diuretic use, or history of acute kidney injury 1, 2, 1
- Monitor for symptoms of volume depletion and hypotension after initiation 1
Foot ulcers or prior amputation:
- Use with caution in patients with severe peripheral neuropathy or history of amputation 2, 7
- Canagliflozin specifically showed increased amputation risk in CANVAS trial 7
Immunosuppression:
- SGLT2 inhibitors have not been adequately studied in kidney transplant recipients who may be at increased risk for infections 1
Implementation Strategy
Adding SGLT2 Inhibitors to Current Therapy
If patient is meeting glycemic targets:
- Add SGLT2 inhibitor for cardiovascular and renal protection regardless of HbA1c 1, 2, 1
- Consider reducing or stopping sulfonylureas or insulin to prevent hypoglycemia 1, 9
- Do not reduce metformin dose 1
If patient is not meeting glycemic targets:
Pre-Initiation Assessment
Check for hypoglycemia risk:
- If on insulin or sulfonylurea with HbA1c at or below goal, reduce insulin dose by ~20% or reduce sulfonylurea dose 2, 7, 9
- History of severe hypoglycemia warrants dose adjustment of background therapy 2
Assess volume status:
- If high risk (concurrent diuretics, tenuous volume status, history of AKI), consider diuretic dose reduction 2, 1
- Educate on volume depletion symptoms 2, 1
Patient education must include:
- Genital hygiene to prevent mycotic infections 6, 2
- "Sick day" protocol: temporarily withhold during illness, excessive exercise, or alcohol intake; maintain hydration; check glucose and ketones more frequently 2, 9
- Signs of diabetic ketoacidosis: shortness of breath, nausea, vomiting, abdominal pain, confusion, excessive thirst, lethargy 6, 9
Monitoring and Follow-Up
Expected eGFR Changes
Anticipate an acute eGFR decline of 3-5 mL/min/1.73 m² within the first 4 weeks:
- This reversible decrease is generally not an indication to discontinue therapy 1, 4
- The decline reflects hemodynamic changes (reduced glomerular hyperfiltration) and does not signal kidney injury 4, 10
- eGFR typically stabilizes after the initial dip 4
Continuation at Low eGFR
Once initiated, continue SGLT2 inhibitors even if eGFR falls below the initiation threshold:
- Reasonable to continue even if eGFR falls below 20 mL/min/1.73 m² 1, 4
- Discontinue only if not tolerated or when kidney replacement therapy (dialysis or transplantation) is initiated 1, 4
- Post-hoc analysis of CREDENCE showed persistent cardiovascular and kidney benefits when eGFR fell <20 mL/min/1.73 m² with no additional safety concerns 11
Adverse Event Monitoring
- Genital mycotic infections: Most common adverse effect; counsel on hygiene and treat with antifungals without stopping SGLT2 inhibitor 6, 9
- Hypoglycemia: Monitor if on insulin or sulfonylureas; adjust background therapy as needed 2, 9
- Volume depletion: Re-assess volume status and symptoms at follow-up 2, 1
- Diabetic ketoacidosis: Rare but serious; measure blood glucose and ketones if symptoms develop 6, 9
- Acute kidney injury: Increased monitoring warranted in those at risk, but initial eGFR decline is expected and not harmful 6, 4
Common Pitfalls to Avoid
Do not discontinue SGLT2 inhibitors due to initial eGFR decline:
- The expected 3-5 mL/min/1.73 m² drop in the first month is hemodynamic, reversible, and does not indicate kidney damage 1, 4
Do not wait for optimal glycemic control before initiating:
- Cardiovascular and renal benefits occur independent of glucose-lowering effect 2, 3
- Initiate based on cardiovascular and renal indications regardless of HbA1c 2, 3
Do not stop SGLT2 inhibitors when eGFR falls below initiation threshold:
Do not forget perioperative management:
- Withhold at least 2-3 days before scheduled surgery requiring fasting or bowel preparation 2, 7
- Measure glucose and ketones on hospital admission; proceed if ketones ≤1.0 mmol/L 2
- Restart after procedure when patient is eating and drinking normally 2
Do not overlook sick-day education: